Genmab HexaBody - Model CD38 (GEN3014) - Novel Human Monoclonal Antibody
GEN3014 (HexaBody®-CD38) is a novel human CD38 monoclonal antibody incorporating Genmab’s HexaBody® technology. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen Biotech Inc. to develop and commercialize HexaBody®-CD38. In preclinical models of hematological malignancies, HexaBody®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor activity.
Clinical Trials
A phase 1 clinical study of HexaBody®-CD38 in hematological malignancies is ongoing.
Customer reviews
No reviews were found for Genmab HexaBody - Model CD38 (GEN3014) - Novel Human Monoclonal Antibody. Be the first to review!